WASHINGTON (Reuters) - A Novartis AG promotion for Alzheimer’s drug Exelon made misleading claims about the medicine’s effectiveness and risks, U.S. health officials warned the company in a letter released on Tuesday.
WASHINGTON (Reuters) - A Novartis AG promotion for Alzheimer’s drug Exelon made misleading claims about the medicine’s effectiveness and risks, U.S. health officials warned the company in a letter released on Tuesday.
